Table 2.

Component calculations for ASCO NHB scores and ESMO MCBS grades for maintenance PARPi based on germline- and somatic-biomarkers

	Study 19		SOLO 2	NOVA			ARIEL3
ASCO NHB	gBRCA	wBRCA, HRD (−)	gBRCA	gBRCA	HRD	wBRCA, HRD (−)	gBRCA	HRD	wBRCA, HRD (−)
Clinical Benefit	66	36	56	58	50	34	62	45	34
Toxicity	(−)4	(−)4	(−)9	(−)8	(−)8	(−)8	(−)8	(−)8	(−)8
Tail of the curve	-	-	-	-	-	-	-	-	-
Palliation of symptoms	-	-	-	-	-	-	-	-	-
TFI	-	-	-	-	-	-	-	-	-
QOL	0	0	0	0	0	0	0	0	0
Final NHB score	62	32	47	50	42	26	54	57	26
ESMO MCBS
Clinical Benefit	3	2	3	3	3	2	3	3	2
Toxicity	0	0	0	0	0	0	0	0	0
QOL	0	0	0	0	0	0	0	0	0
Final adjustments	(+)1*	-	(+)1*	(+)1*	(+)1*	-	(+)1*	(+)1*	(+)1*
Final MCBS grade	4	2	4	4	4	2	4	4	3

ASCO = American Society of Clinical Oncology; NHB = Net Health Benefit; ESMO = European Society of Medical Oncology; MCBS = Magnitude of Clinical Benefit Scale; QOL = quality of life; TFI = treatment-free interval; HRD = homologous recombination deficiency; gBRCA = germline BRCA mutation; wBRCA = wild-type BRCA gene

^*Upgrade for long-term plateau in PFS and >10% improvement in PFS at 1 year.